Incyte | INCY - Selling And Administration Expenses

Stock Price
101.32
Daily Change
-0.41 -0.40%
Monthly
-3.20%
Yearly
40.51%
Q1 Forecast
98.18

Incyte reported $390.41M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 124.9M 1.24M Sep/2025
Agenus USD 23.6M 448K Sep/2025
Agios Pharmaceuticals USD 42.97M 1.7M Dec/2025
Alnylam Pharmaceuticals USD 285.06M 22.47M Dec/2025
Amgen USD 1.94B 237M Dec/2025
BioCryst Pharmaceuticals USD 80.47M 15.39M Dec/2024
Biogen USD 545.2M 38.6M Sep/2025
BioMarin Pharmaceutical USD 223.42M 8.86M Sep/2025
Bristol-Myers Squibb USD 2.18B 392M Dec/2025
Eli Lilly USD 3.13B 391.3M Dec/2025
Exelixis USD 123.02M 19.9M Dec/2025
Gilead Sciences USD 1.78B 425M Dec/2025
Incyte USD 390.41M 61.33M Dec/2025
Ionis Pharmaceuticals USD 86.56M 4.04M Sep/2025
MacroGenics USD 9.9M 600K Sep/2025
Merck USD 2.85B 215M Dec/2025
Moderna USD 308M 40M Dec/2025
Nektar Therapeutics USD -0.18 0.07 Sep/2024
Neurocrine Biosciences USD 301.8M 10.2M Dec/2025
Novartis USD 3.31B 134M Sep/2025
Novartis USD 3.3B 137M Sep/2025
Pfizer USD 4.08B 894M Dec/2025
PTC Therapeutics USD 87.2M 3.15M Dec/2025
Puma Biotechnology USD 16.82M 8.15M Sep/2024
Regeneron Pharmaceuticals USD 775M 117.2M Dec/2025
Sarepta Therapeutics USD 77.11M 7.22M Sep/2025
Ultragenyx Pharmaceutical USD 89M 2.38M Dec/2025
Vertex Pharmaceuticals USD 487M 41.9M Dec/2025